GlassScriptPhysician profile
Brian Christopher Johnston
NPI 1104322007
$3,632.00
in general payments reported to CMS, 2019-2025
28 companies · $813 in 2025
The $813 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,025 · 2023: $1,117 · 2024: $678 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $472.98 | 2022-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $453.38 | 2022-2024 | Xarelto |
| Csl Behring | $410.45 | 2022-2025 | Kcentra |
| Shionogi INC | $306.28 | 2022-2024 | Fetroja |
| Abbvie INC. | $282.41 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.78 | 2022-2024 | Xifaxan |
| Pfizer INC. | $199.97 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.87 | 2022-2025 | Jardiance |
| Ferring Pharmaceuticals INC. | $152.95 | 2023-2025 | Rebyota |
| Vifor Pharma, INC. | $124.40 | 2022-2023 | Veltassa |
| Merck Sharp & Dohme LLC | $123.80 | 2022-2024 | Dificid |
| Astrazeneca Pharmaceuticals LP | $110.14 | 2022-2025 | Lokelma, Farxiga |
| Alexion Pharmaceuticals, INC. | $88.94 | 2022-2025 | Ultomiris |
| Novo Nordisk INC | $63.30 | 2025 | Ozempic, Wegovy |
| Sumitomo Pharma America, INC. | $62.09 | 2025 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $53.07 | 2023 | Arikayce |
| Sanofi-Aventis U.S. LLC | $45.32 | 2025 | |
| Boston Scientific Corporation | $43.11 | 2025 | Apollo Esg System |
| Novartis Pharmaceuticals Corporation | $31.86 | 2023 | |
| Astellas Pharma US INC | $27.93 | 2025 | Veozah |
| Aimmune Therapeutics, INC. | $25.02 | 2025 | Vowst |
| Shield Therapeutics INC | $23.44 | 2025 | |
| Gilead Sciences, INC. | $22.53 | 2025 | |
| Dynavax Technologies Corporation | $19.23 | 2025 | Heplisav-B |
| Vertex Pharmaceuticals Incorporated | $17.44 | 2025 | |
| Melinta Therapeutics, LLC | $17.01 | 2025 | Rezzayo |
| Lilly USA, LLC | $16.62 | 2025 | Kisunla |
| Dexcom, INC. | $14.68 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.